In vivo, LRA<sup>FAP</sup> showed enhanced accumulation in CAF-enriched tumours and an increase in intratumoural oxaliplatin levels of approximately 2.5-fold relative to oxaliplatin alone. This evidence concerns the gene FAP and neoplasm.